Business Context and Reporting Period
Zimmer Biomet Holdings, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2025. The company is a leading global medical technology company focused on orthopedic reconstructive products, sports medicine, and surgical technologies. The reporting period includes the impact of the completed acquisition of Paragon 28, Inc. on April 21, 2025, and ongoing restructuring initiatives.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Sales | $2,077.3 million | $3,986.4 million |
| Operating Profit | $300.0 million | $592.3 million |
| Net Earnings (Zimmer Biomet) | $152.8 million | $334.9 million |
| Diluted EPS | $0.77 | $1.68 |
| Operating Cash Flow (6mo) | $761.0 million | |
| Total Debt (Current + Long-term) | $7,572.5 million | |
| Cash and Cash Equivalents | $556.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.0% year-over-year (Q2) and 4.0% (YTD), driven by the Paragon 28 acquisition (contributing 2.6% and 1.4% respectively), market growth, and favorable foreign currency impacts.
- Profitability Decline: Net earnings decreased significantly to $152.8 million (Q2) and $334.9 million (YTD) compared to $242.8 million and $415.2 million in the prior year. This was primarily due to acquisition-related costs, higher interest expense from new debt, increased manufacturing costs (inflation), and higher intangible asset amortization.
- Acquisition Impact: The Paragon 28 acquisition resulted in $78.9 million in acquisition-related expenses for Q2 and $89.5 million YTD. Goodwill increased by $643.1 million related to this transaction.
- Debt Structure: The company redeemed $863.0 million of senior notes due in 2025 and issued $1.748 billion in new senior notes (due 2027, 2030, and 2035) to fund the Paragon 28 acquisition and general corporate purposes.
- Restructuring: Restructuring charges decreased to $17.5 million (Q2) and $53.5 million (YTD) compared to $41.5 million and $165.9 million in the prior year, reflecting the timing of the 2025 Restructuring Plan versus the 2023 plan.
Guidance, Outlook, and Risks
- 2025 Outlook: Management expects full-year 2025 revenue growth of 6.7% to 7.7%. Net earnings are expected to decrease compared to 2024 due to higher acquisition costs, operating expenses, amortization, interest expense, and a higher effective tax rate.
- Tariff Impact: The company anticipates recognizing approximately $40 million in additional expenses related to tariffs in 2025, with a more significant impact expected in the second half of the year.
- Future Acquisitions: On July 11, 2025, the company entered into an agreement to acquire Monogram Technologies Inc. for approximately $180 million in initial consideration, with up to $570 million in contingent value rights.
- Tax Risks: The IRS has proposed adjustments for tax years 2013-2019, which could result in additional material tax expense (approx. $312 million for 2016-2019) if the company is unsuccessful in defending its position. The company is also evaluating the impact of the "One Big Beautiful Bill Act" signed into law on July 4, 2025.
- Litigation: Accrued litigation liabilities were $156.8 million as of June 30, 2025. The company faces ongoing product liability claims and intellectual property disputes.
Investor Verification Checklist
- Paragon 28 Integration: Verify the realization of synergies and the impact of stepped-up inventory fair value on future margins.
- Debt Servicing: Confirm the ability to service the increased debt load ($7.57 billion total) given the higher interest rates on new issuances.
- Tax Resolution: Monitor the status of IRS disputes for tax years 2013-2019 and the potential $312 million liability.
- Tariff Exposure: Assess the actual impact of tariffs on cost of goods sold in the second half of 2025 against the $40 million estimate.
- Monogram Acquisition: Track regulatory approval and closing conditions for the Monogram Technologies acquisition.